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Dear Sir,
We read with great interest the paper by Afolabi et al.
[1]. It is true that 13C-liver function breath tests (13C-
LFBTs) appear to be attractive both to patients and phy-
sicians because of their non-invasive protocol, as opposed
to diagnostic procedures infringing the body integrity,
which inherently entails a liver biopsy. Unfortunately, after
almost three decades during which 13C-LFBTs were
available to clinicians, those tests still have not paved their
way to become a routine diagnostic tool. The breakthrough
made by the quoted paper consists in the clear delineation
of targets for future research which, if attained, should gain
an objective view upon the clinical usefulness of those
tests. Accordingly, phase one of this validation process
should involve evaluation of reproducibility, the second
one involves the assessment of prognostic utility, and
ultimately the third phase should investigate the effect of
13C-LFBTs upon the patients’ outcome [1].
One should be aware that the result of a breath test, like
in the case of any other quantitative diagnostic method
applied in medicine, may contain a certain degree of
inexactitude because an immanent feature of any mea-
surement is its proneness to random as well as systematic
errors. Therefore it is necessary to identify possible sources
of measurement errors and to estimate of their contribution
to the overall error of a diagnostic method and, as the
ultimate step, to undertake means to possibly minimize it.
In the case of 13C breath tests, the total measurement
error will be accounted for by the precision and exactitude
of the apparatus used to determine the content of 13CO2
within samples of the expired air, degree of conformity
with the recommended protocol of accomplishing the test,
and inherent biological variability of the living organism
undergoing a diagnostic procedure.
The error introduced by the measurement equipment is
relatively easy to estimate, because it will be characterized
by sensitivity, linearity range, as well as by within- and
between-series consistency of measurement results. Those
items are basically addressed by manufacturers, and a daily
routine of calibration assures the maintenance of optimum
performance of the equipment. Knowledge of the perfor-
mance of the measuring system is of course necessary to
adjust an optimum dosage of the 13C-labeled substrate
applied for a given breath test [2].
Minimization of the error associated with the imple-
mentation of a breath test is achieved by standardization of
the composition and method of preparing a test meal, the
time allowed for its consumption, number, time intervals
and the method of sampling the expiratory air, as well as
the ambiance offered to the examined subjects while
undergoing the examination. The set of interventions usu-
ally undertaken in this respect comprises advice and rec-
ommendations given to subjects with regard to some
restrictions that have to be observed before an examination
(like remaining fasting, abstaining from smoking ciga-
rettes, withdrawal of use of medication), and the behavior
during the test (avoidance of physical activity, maintenance
of a recommended body position, refraining from smoking
and from taking meals or drinks other than that provided by
the laboratory staff) [3–6].
Measures undertaken in an attempt to control the error
introduced by biological variability may consist in a strict
observation of a constant time of day when the test is
performed, or, in the case of women at a reproductive
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age—in taking into account their menstrual cycle status
[7, 8].
We totally agree with Afolabi et al. [1] that a valuable
tool enabling the assessment of the performance of a
quantitative measurement in medicine is the determination
of the reproducibility of the results it provides. An esti-
mation of the gross error of the diagnostic method,
accounted for by the factors and circumstances described
above, can be thus obtained. Consequently, a poor repro-
ducibility of a test will in fact determine its unsuitability
for clinical applications, since it means that the results of
tests performed in the same person under identical condi-
tions may largely differ from one another [9].
It is our pleasure to provide herein additional data on
reproducibility of the 13C-LFBTs, not reported in the
paper by Afolabi et al. [1]. In our laboratory we pursued
prospective evaluation of the reproducibility of the 13C-
methacetin breath test (13C-Meth-BT) [10], the 13C-alpha-
ketoisokaproic acid breath test (13C-KICA-BT) [11], and
the 13C-phenylalanine breath test (13C-PhenAla-BT) [12].
Thus, insight on the precision of the representatives of
three main groups of the 13C-LFBTs has been obtained,
since the 13C-Meth-BT evaluates the microsomal liver
metabolism, whereas the 13C-KICA-BT and the 13C-
PhenAla-BT are dedicated to assess the mitochondrial and
the cytosolic metabolic efficiency of the liver, respec-
tively. The results of the short-term (repeat examination
were taken 1–3 days apart) and the medium-term (the
repeat measurements were separated by a 2–3-week
break) reproducibility of the three 13C-LFBTs are
assembled in Table 1. The common denominator of those
data is that Tmax—the time to reach the peak of
13CO2
concentration in expiratory air—is considerably less
reproducible than the two other quantitative parameters of
the 13C-LFBTs, namely, the maximum momentary elim-
ination (Dmax) which is characterized by a fair repro-
ducibility, and the best reproducible cumulative
elimination of 13C in breath air, conveyed as the area
under the 13C elimination curve (AUC). In no instance
did the medium-term reproducibility prove any worse
than the short-term one (Table 1). Quite strikingly, taking
into account the magnitude of the pertinent coefficients of
variation for paired examinations (CVp), the reproduc-
ibility of the 13C-PhenAla-BT appears to be remarkably
worse than in the case of either the 13C-Meth-BT or 13C-
KICA-BT. The latter finding raises concerns whether the
precision of the 13C-PhenAla-BT may be sufficient to
yield clinically sound conclusions.
Detailed analyses of the reproducibility data referred in
this correspondence have been published elsewhere [10,
11]. In summary, we would like to recall some important
observations. First, in the case of 13C-Meth-BT it was
found that on repeat examinations the exactitude of AUC
may be modestly affected by a persistent stimulation of
CYP1A2 responsible for a fixed bias which amounted to
8 % [10]. Second, achievement of a necessary reproduc-
ibility level of the 13C-KICA-BT requires calculation of the
AUC for a time span from within the range between 0 and
90 min or even better, for 0–120 min [11].
We do hope that the data and remarks contained herein
supplement and support the idea of systematic validation of
13C-LFBTs outlined in the paper by Afolabi et al. [1].
Table 1 Reproducibility of three liver breath tests
Parameter Dmax Tmax AUC0–60 AUC0–90
S_term M_term S_term M_term S_term M_term S_term M_term
13C-methacetin breath test
CVp 16.2 % 16.5 % 30.6 % 32.5 % 10.0 % 10.0 % 9.2 % 8.7 %
RC 15.6 % dose/h 16.8 % dose/h 16.9 min 16.7 min 5.8 % dose 5.9 % dose 7.0 % dose 6.8 % dose
D0.05 (N = 20) 3.8 % dose/h 3.5 % dose/h 4.0 min 3.8 min 1.4 % dose 1.3 % dose 1.8 % dose 1.4 % dose
13C-alpha-ketoisokaproic acid breath test
CVp 11.2 % 13.9 % 20.0 % 24.8 % 12.6 % 12.4 % 8.2 % 9.0 %
RC 7.4 % dose/h 9.5 % dose/h 15.9 min 19.6 min 5.4 % dose 5.4 % dose 5.1 % dose 5.7 % dose
D0.05 (N = 14) 2.2 % dose/h 2.9 % dose/h 4.3 min 5.2 min 1.6 % dose 1.5 % dose 1.6 % dose 1.6 % dose
13C-phenylalanine breath test
CVp 28.5 % 27.2 % 35.2 % 30.0 % 25.9 % 25.9 % 21.6 % 21.1 %
RC 11.6 % dose/h 10.8 % dose/h 17.8 min 15.6 min 5.4 % dose 5.2 % dose 5.9 % dose 5.6 % dose
D0.05 (N = 12) 3.9 % dose/h 3.6 % dose/h 6.0 min 5.3 min 1.8 % dose 1.7 % dose 2.0 % dose 1.9 % dose
Dmax maximum momentary
13C elimination, Tmax time to reach the Dmax, AUC0–60 and AUC0–90 60-min and 90-min cumulative
13C elimination
in expiratory air, respectively, S_term and M_term short-term and medium-term reproducibility, respectively, CVp coefficient of variation for
paired examinations [13], RC repeatability coefficient [14], D0.05 = the least difference detectable at p = 0.05 level, two-tailed in the case of N
paired examinations
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